OR WAIT null SECS
August 11, 2026
Article
The FDA accepted EIT Pharma’s lonafarnib NDA for chronic hepatitis D, supported primarily by the phase 3 D-LIVR trial.
August 10, 2026
FDA grants volixibat Breakthrough Therapy and Orphan Drug status for PSC pruritus, but recommends an additional phase 3 trial before NDA.
August 06, 2026
Video
Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.
August 04, 2026
Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA
July 28, 2026
Topline data from the largest disease-modification trial in biliary atresia show no benefit over placebo for the primary endpoint, though the established safety profile in approved indications was maintained.
World Hepatitis Day survey findings reveal gaps in chronic hepatitis B awareness and liver cancer risk perception, with Cary James discussing elimination efforts.
July 24, 2026
Telehealth stepped alcohol treatment reduced weekly drinking, but not the primary endpoint, among patients with chronic liver disease.
July 22, 2026
Monopar initiated a rolling NDA submission for ALXN1840, an investigational therapy for Wilson disease targeting copper dysregulation.
Phase 2 data suggest zabopegdutide improved liver fat, stiffness, and fibrosis biomarkers within 12 weeks in adults with MASH.
July 13, 2026
Stevan Gonzalez, MD, MS, explains patient characteristics and social determinants of health associated with chronic liver disease.
